Aim 1: Primary Prevention of Post-operative Cardiac Arrhythmias
To evaluate the efficacy of dexmedetomidine vs. the combination of Magnesium Sulfate and dexmedetomidine for the prevention of post-operative cardiac arrhythmias in children and young adults undergoing open heart surgical repair for congenital or acquired heart disease using cardiopulmonary bypass. Dexmedetomidine is currently being administered to almost all patients after coming off cardiopulmonary bypass and in the CICU. For this aim, the investigator will be comparing dexmedetomidine administered alone or in combination with Magnesium Sulfate.
To evaluate medication safety based on the frequency of Serious Adverse Events (SAEs) and Adverse Events (AEs)
Aim 2: Secondary treatment of those Patients that develop a clinically significant arrhythmia despite having received either Dexmedetomidine alone or Magnesium Sulfate with Dexmedetomidine at the time of cardiac surgery
To evaluate the efficacy of intravenous (IV) Amiodarone vs. IV Procainamide for the control of postoperative cardiac arrhythmias developing after the failure of Stage 1, Preventative Trial. IV amiodarone and IV procainamide are standardly used treatment agents for the treatment of postoperative cardiac arrhythmias in this setting. The investigator will be assessing the comparative effectiveness of these agents in controlling post-operative cardiac arrhythmias.
To evaluate antiarrhythmic medication safety based on the frequency of SAEs and AEs

开始日期2023-01-01

申办/合作机构

Children's National Research Institute

NCT05343312 / Active, not recruiting临床4期IIT

Monitoring the Therapeutic Efficacy of the Combinations Artemether-Lumefantrine, Amodiaquine-Artesunate, Dihydroartemisinin-Piperaquine, and Pironaridine-Artesunate in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Under 5 Years of Age in Five Sentinel Sites in Mozambique

This is a classical in vivo clinical trial, following World Health organization's recommendations, ran as a multisite study within Mozambique trying to assess the efficacy and safety in 5 sites of the four oral ACTS artemether-lumefantrine (AL), Amodiaquine-Artesunate (AQ-AS), Dihydroartemisinin-Piperaquine (DHP) and Pironaridine-Artesunate for the treatment of uncomplicated malaria in children aged<5 years.

开始日期2022-03-16

申办/合作机构-

NCT04485195 / Recruiting临床4期IIT

RAFF4 Trial: Vernakalant vs. Procainamide for Acute Atrial Fibrillation in the Emergency Department

The objective is to compare IV vernakalant to IV procainamide for the ED management of acute AF patients. If vernakalant proves to be more effective, faster, and safer than IV procainamide, this will give clinicians an important alternative for pharmacological cardioversion of acute AF. The investigators propose a pragmatic comparative effectiveness trial entailing an open label, randomized controlled trial at 12 large Canadian EDs. Study subjects will be randomized to 1 of 2 treatment arms: 1) Patients will receive an initial infusion of 3mg/kg of IV vernakalant over 10 minutes, followed by a second dose of 2mg/kg over 10 minutes, if necessary, or 2) Patients will receive a continuous infusion of 15mg/kg of IV procainamide over 60 minutes. The primary aim will be to compare conversion to normal sinus rhythm between the two drugs. The investigators will include stable patients presenting with an episode of acute AF of at least 3 hours duration, where symptoms require urgent management and where immediate cardioversion is a reasonable option. Using the integrated consent model, research assistants will obtain verbal consent from eligible patients.

开始日期2021-06-17

申办/合作机构

Ottawa Hospital Research Institute

100 项与盐酸普鲁卡因胺相关的临床结果

登录后查看更多信息

100 项与盐酸普鲁卡因胺相关的转化医学

登录后查看更多信息

100 项与盐酸普鲁卡因胺相关的专利（医药）

登录后查看更多信息

7,320

项与盐酸普鲁卡因胺相关的文献（医药）

2024-12-01·Cellular and molecular life sciences : CMLS

Dysregulated palmitic acid metabolism promotes the formation of renal calcium-oxalate stones through ferroptosis induced by polyunsaturated fatty acids/phosphatidic acid

Article

作者: Liu, Chunyu ; Ren, Haotian ; Wang, Rui ; Zhang, Jingdong ; Xie, Haijie ; Xie, Linguo ; Shang, Zhiqun ; Qi, Shiyong

Abstract:

The pathogenesis of renal calcium-oxalate (CaOx) stones is complex and influenced by various metabolic factors. In parallel, palmitic acid (PA) has been identified as an upregulated lipid metabolite in the urine and serum of patients with renal CaOx stones via untargeted metabolomics. Thus, this study aimed to mechanistically assess whether PA is involved in stone formation. Lipidomics analysis of PA-treated renal tubular epithelial cells compared with the control samples revealed that α-linoleic acid and α-linolenic acid were desaturated and elongated, resulting in the formation of downstream polyunsaturated fatty acids (PUFAs). In correlation, the levels of fatty acid desaturase 1 and 2 (FADS1 and FADS2) and peroxisome proliferator-activated receptor α (PPARα) in these cells treated with PA were increased relative to the control levels, suggesting that PA-induced upregulation of PPARα, which in turn upregulated these two enzymes, forming the observed PUFAs. Lipid peroxidation occurred in these downstream PUFAs under oxidative stress and Fenton Reaction. Furthermore, transcriptomics analysis revealed significant changes in the expression levels of ferroptosis-related genes in PA-treated renal tubular epithelial cells, induced by PUFA peroxides. In addition, phosphatidyl ethanolamine binding protein 1 (PEBP1) formed a complex with 15-lipoxygenase (15-LO) to exacerbate PUFA peroxidation under protein kinase C ζ (PKC ζ) phosphorylation, and PKC ζ was activated by phosphatidic acid derived from PA. In conclusion, this study found that the formation of renal CaOx stones is promoted by ferroptosis of renal tubular epithelial cells resulting from PA-induced dysregulation of PUFA and phosphatidic acid metabolism, and PA can promote the renal adhesion and deposition of CaOx crystals by injuring renal tubular epithelial cells, consequently upregulating adhesion molecules. Accordingly, this study provides a new theoretical basis for understanding the correlation between fatty acid metabolism and the formation of renal CaOx stones, offering potential targets for clinical applications.

2024-11-21·Journal of biomolecular structure & dynamics

Computational assessment of lipid facilitated membrane permeation of vancomycin using force-probe molecular dynamic simulation

Article

作者: Shahlaei, Mohsen ; Ansari, Mohabbat ; Hosseinzadeh, Simzar ; Moradi, Sajad

In this study the efficacy of different edible lipids for drug permeation enhancement of vancomycin through biological membrane was investigated using molecular dynamic simulation. In this regard, at first the ability of the lipids for complex formation with the drug was evaluated for number of most common edible lipids including tripalmitin (TPA), trimyristin (TMY), labrafil (LAB), glycerol monostearate (GMS), glycerol monooleate (GMO), Distearoylphosphorylethanolamine (DSPE), dipalmitoylphosphatidylethanolamine (DPPE), Dipalmitoylphosphatidylcholine (DPPC), cholesterol (CL), stearic acid (SA), palmitic acid (PA) and oleic acid (OA). Then the complexes were pulled thorough a bilayer membrane while the changes in force were probed. The results showed that besides the SA, PA and OA the other examined lipids were able to perform a perfect molecular complex with the drug. Also the results of pulling simulation revealed that the least of force was needed for drug transmittance through the membrane when it was covered by LAB, TMY and DSPE. These results indicated that these lipids can be the excellent materials of choice as permeation enhancer for preparing a proper oral formulation of vancomycin.Communicated by Ramaswamy H. Sarma.

2024-10-01·Molecular neurobiology

Amelioration of Phytanic Acid–Induced Neurotoxicity by Nutraceuticals: Mechanistic Insights

Review

作者: Chaudhary, Shaista ; Tiwari, Prachi ; Parvez, Suhel ; Neha

Phytanic acid (PA) (3,7,11,15-tetramethylhexadecanoic acid) is a methyl-branched fatty acid that enters the body through food consumption, primarily through red meat, dairy products, and fatty marine foods. The metabolic byproduct of phytol is PA, which is then oxidized by the ruminal microbiota and some marine species. The first methyl group at the 3-position prevents the β-oxidation of branched-chain fatty acid (BCFA). Instead, α-oxidation of PA results in the production of pristanic acid (2,10,14-tetramethylpentadecanoic acid) with CO₂. This fatty acid (FA) builds up in individuals with certain peroxisomal disorders and is historically linked to neurological impairment. It also causes oxidative stress in synaptosomes, as demonstrated by an increase in the production of reactive oxygen species (ROS), which is a sign of oxidative stress. This review concludes that the nutraceuticals (melatonin, piperine, quercetin, curcumin, resveratrol, epigallocatechin-3-gallate (EGCG), coenzyme Q10, ω-3 FA) can reduce oxidative stress and enhanced the activity of mitochondria. Furthermore, the use of nutraceuticals completely reversed the neurotoxic effects of PA on NO level and membrane potential. Additionally, the review further emphasizes the urgent need for more research into dairy-derived BCFAs and their impact on human health.

项与盐酸普鲁卡因胺相关的新闻（医药）

2024-01-13

·生物探索

Gut | 中山大学郭剑平/匡铭揭示高脂肪饮食通过棕榈酰化和AKT的激活促进肝脏肿瘤的发生

作为代谢稳态的中心节点，PI3K-AKT通路是否以及如何导致高脂肪诱导的非酒精性脂肪性肝炎(NASH)和肝细胞癌(HCC)仍然是一个谜。2024年1月8日，中山大学郭剑平及匡铭共同通讯在Gut（IF=25）在线发表题为“High-fat diet promotes liver tumorigenesis via palmitoylation and activation of AKT”的研究论文，该研究发现高脂肪饮食通过棕榈酰化和AKT的激活促进肝脏肿瘤的发生。通过筛选代谢物库，该研究发现PA通过促进棕榈酰修饰激活AKT，这是生长因子诱导AKT激活的必要步骤。在生物学上，高脂肪饮食可以促进AKT激酶活性，从而促进NASH和肝癌。从机制上讲，棕榈酰结合以不依赖PIP3的方式将AKT锚定在细胞膜上，部分原因是通过阻止AKT组装成非活性聚合物。棕榈酰转移酶ZDHHC17/24被表征为棕榈酰化AKT发挥致癌作用。有趣的是，抗肥胖药物奥利司他或特异性穿透肽可分别通过限制PA合成或抑制AKT修饰有效减弱AKT棕榈酰化和活化，从而拮抗肝脏肿瘤发生。该研究阐明了PA-ZDHHC17 /24介导的棕榈酰化对AKT的一种新的微调调节，并强调了通过限制PA饮食、限制PA合成或直接靶向AKT棕榈酰化来治疗肿瘤的策略。饮食不仅为肿瘤细胞不受控制的生长提供营养和基础，而且还促进信号转导，影响肿瘤的各个方面，因此饮食改变疗法最近已经实现，包括热量限制和低热量脂肪饮食。值得注意的是，高脂肪饮食(HFDs)主要与代谢性疾病相关，包括肥胖和癌症，其机制多样且尚不清楚。其中，棕榈油是最主要的膳食油来源之一，也是肥胖的主要原因之一，被认为是一种代谢性疾病，倾向于诱发肿瘤。值得注意的是，PA作为棕榈脂和动物脂肪油的主要成分，其代谢功能形成细胞质膜，与口腔肿瘤转移密切相关。同时，PA的活性产物棕榈酰辅酶A已被证明可诱导多种蛋白的棕榈酰修饰，如MC1R对紫外线诱导的黑色素瘤起作用，STAT3对IL-6诱导的Th17分化和抗病毒感染起作用，N-RAS对结肠癌起作用。然而，合成或食物摄取的PA积累是否以及如何参与肿瘤发生，特别是参与代谢稳态的器官，如肝脏，尚不清楚。HFD一直被认为是非酒精性脂肪性肝炎(NASH)的一个不减弱的危险因素，NASH是一种非酒精性脂肪性肝病(NAFLD)的晚期形式，现在也被称为代谢功能障碍相关的脂肪性肝炎。NASH涉及小叶炎症、纤维化和肝细胞膨胀，可发展为HCC。尽管自噬和免疫反应等多种潜在机制与NASH相关，但作为代谢稳态的中心节点，在脂肪生成和HCC进展中发挥重要作用的PI3K-AKT通路是否以及如何导致高脂肪诱导的NASH和HCC仍是一个谜。棕榈酰化增强AKT活性和致癌功能的模型（图源自Gut ）PI3K-AKT通路作为响应细胞外刺激的中心信号，在生理上对细胞生长、存活和代谢稳态起着关键作用，在病理上对糖尿病和肿瘤发生也起着关键作用。因此，AKT的调控，特别是在翻译后水平，已被广泛确立。值得注意的是，AKT PH结构域与PI3K生成的PIP3的结合被认为是通过PDK1介导的T308和mTORC2介导的S473磷酸化完全激活AKT的关键步骤。例如，泛素化、乙酰化和甲基化都有助于AKT与PIP3的结合，从而进一步激活PIP3。因此，PIP3相关酶的遗传改变，包括其激酶PIK3CA、磷酸酶PTEN及其上游调节蛋白，如RAS和EGFR，已在大约50%的不同类型的癌症中被观察到，这在很大程度上有助于PIP3的积累和随后的AKT激活。为此，针对PIK3CA-H1047R突变体的特异性抑制剂已被批准用于乳腺癌干预。然而，除了典型的PI3K-PIP3依赖性AKT激活外，AKT是否以及如何以PIP3独立的方式激活尚不清楚。该研究报道了从HFDs中积累PA或异常合成促进ZDHHC17 /24-以PIP3不依赖的方式催化棕榈酰化和激活AKT，导致NASH和肝脏肿瘤发生，并强调了靶向PA-ZDHHC-AKT轴治疗HCC的策略。参考文献：Bu L, Zhang Z, Chen J, Fan Y, Guo J, Su Y, et al. High-fat diet promotes liver tumorigenesis via palmitoylation and activation of AKT. Gut. 2024 Jan 8:gutjnl-2023-330826. doi: 10.1136/gutjnl-2023-330826. Epub ahead of print. PMID: 38191266. 责编|探索君排版|探索君文章来源|“iNature”End往期精选围观王晓红教授团队：绘制单次冷冻囊胚移植成功的女性植入期外周血microRNA动态表达谱，开拓领域创新研究热文维生素B12在细胞重编程与组织再生中发挥关键作用！热文不孕症治疗新方向！又一导致女性不孕的关键因素被发现热文Let-7家族miRNA或为癌症潜在免疫治疗靶点热文一项最新发现或可用于阿尔茨海默病药物开发点击“阅读原文”，了解更多~

ASH会议

2023-11-15

·奇点网

促癌的MYC让癌细胞狂吸维生素B5~

*仅供医学专业人士阅读参考众所周知，肿瘤是异质性的。近年来，单细胞测序技术和空间基因组学的飞速发展，让我们对肿瘤的异质性有了更清晰的认知。这些进步也让科学家有机会了解肿瘤的进化、分类和耐药等问题。肿瘤的代谢，也是近年来研究的热点领域。既然肿瘤是异质性的，那么肿瘤的代谢必然也是异质性的。不过，目前科学家对于肿瘤代谢异质性的认知还比较少。加深对肿瘤代谢异质性的了解，有望催生新的癌症治疗方法。近日，由弗朗西斯·克里克研究所Mariia Yuneva和Peter Kreuzaler领衔的研究团队，在著名期刊《自然·代谢》发表一项重要研究成果[1]。他们发现，在人类和小鼠三阴性乳腺癌组织中，癌基因MYC高表达的区域，癌细胞中多种维生素转运体SLC5A6表达上调，导致癌细胞对维生素B5的摄取增加，并将其转化为辅酶A，加强三羧酸循环，促进癌细胞的增殖和生长。好消息是，限制维生素B5的摄入，会导致许多由MYC介导的代谢变化发生逆转，并导致肿瘤生长受阻。这意味着，有望从这个角度入手，开发出靶向乳腺癌代谢的抗癌药物。论文首页截图为了探索乳腺癌的代谢异质性，Yuneva团队基于由WNT1驱动的三阴性乳腺细胞系，构建了两个新的细胞系：一个是表达超生理水平MYC的WMhigh（表达红色荧光蛋白tdTomato），另一个正常表达MYC的WMlow（表达绿色荧光蛋白eGFP）。如果将两个细胞系混在一起的话，就是WMmix。在上述两个单细胞系和一个混合细胞系的基础上，他们构建了三个不同类型的乳腺癌小鼠模型。随后，他们检测了三种乳腺癌肿瘤模型的代谢物分布情况。和预期的一样，WMhigh和WMlow单细胞系形成的肿瘤代谢物分布一致性较好，而WMmix形成的肿瘤代谢物与癌细胞克隆一样出现分区情况。三种不同肿瘤模型的代谢和克隆差异在上述数据的基础上，Yuneva团队证实了他们采用的研究方法是稳健可靠的。接下来，他们就开始寻找肿瘤克隆一致性带来的代谢差异。通过对大量代谢通路进行分析，他们发现与WMhigh相关性最强的是泛酸（维生素B5，或者PA）。众所周知，泛酸是辅酶A（CoA）的前体，许多关键的代谢途径都需要辅酶A，包括著名的三羧酸循环以及脂肪酸的生物合成和氧化。因此，他们决定研究泛酸-辅酶A轴与MYC介导的新陈代谢之间的关系。WMhigh与泛酸在空间上重叠为了保险起见，在深入研究之前，Yuneva团队先研究了人体组织样本中WMhigh与泛酸的关系。他们发现，在MYC水平最高或MYC转录特征较强的患者来源异种移植模型（PDXs）中，泛酸水平较高。此外，泛酸水平高也与原发性人类乳腺癌活检组织MYC高表达区域密切相关。这些来自人体的数据，支持他们进一步研究MYC与泛酸代谢之间的联系。在人乳腺癌组织样本中，WMhigh与泛酸在空间上也是重叠的随后，他们使用了一种结合了荧光显微镜、电子显微镜和纳米级二次离子质谱（NanoSIMS）的超高分辨率质谱成像技术，证实在WMhigh区域观察到的泛酸水平升高，是由于细胞自主增加了对泛酸的摄取，然后利用泛酸合成辅酶A等下游代谢产物。成像结果从机制上讲，MYC作为一种转录调控因子，在高表达的情况下会促进多种维生素转运体SLC5A6表达增加，进而促进癌细胞对泛酸的摄取，并将泛酸转化成辅酶A，加强三羧酸循环，促进癌细胞的增殖。Yuneva团队还发现，将乳腺肿瘤细胞系4T1放在缺乏泛酸的条件下培养，它们会停止增殖；而补充辅酶A，可以恢复4T1的增殖。这说明，癌细胞需要泛酸的下游代谢产物辅酶A来维持生长。类似地，小鼠体内的研究也发现，不含泛酸的饮食会限制WMmix肿瘤的生长。泛酸对细胞系和肿瘤生长的影响总的来说，Yuneva团队这项研究发现，在乳腺癌细胞中，MYC通过直接上调转运体SLC5A6的水平，增加了肿瘤内泛酸的水平，而且这是支持MYC调节癌细胞增殖和生物合成程序所必需的。考虑到T细胞的活性也需要高水平的辅酶A，因此Yuneva推测，MYC高表达乳腺癌细胞通过增加对泛酸的吸收，一方面促进自身的增殖，另一方面也限制了免疫细胞的抗癌活性。参考文献：[1].Kreuzaler P, Inglese P, Ghanate A, et al. Vitamin B5 supports MYC oncogenic metabolism and tumor progression in breast cancer. Nat Metab. 2023. doi:10.1038/s42255-023-00915-7本文作者丨BioTalker

AACR会议临床结果临床1期

2023-07-12

·药闻康策

重磅：网售处方药新规定，这些品种网络禁售！

☝ 点击上方一键预约 ☝ 最新最热的医药健康新闻政策日前，国家药监局在官网公布该局综合司关于《药品网络销售禁止清单（第一版）》有关问题的复函，该复函是答复广东省药监局《关于请明确药品网络销售相关问题的函》。答复函对《药品网络销售禁止清单（第一版）》（下称《清单》）中相关药品的处理方式进行了答复。答复函显示：一、《清单》第二项第（二）款“含麻醉药品口服复方制剂”，具体参照《食品药品监管总局办公厅关于进一步加强含麻醉药品和曲马多口服复方制剂购销管理的通知》（食药监办药化监〔2014〕111号）中所列产品名单执行。二、复合包装产品中包含《清单》中第二项第（四）款所列药品的单方制剂，应按照禁售清单要求执行。如：雌二醇片/雌二醇地屈孕酮片复合包装含有单方制剂雌二醇片，属于《清单》中禁止通过网络零售的品种。三、此前已出现的相关产品网售行为，监管部门应当根据上述要求责令相关企业限期整改。逾期不改正的，依法予以处罚。这次是针对《清单》第二项中的含麻醉药品口服复方制剂、右美沙芬口服单方制剂内容的答复：即《清单》第二项第（二）款“含麻醉药品口服复方制剂”，具体参照《食品药品监管总局办公厅关于进一步加强含麻醉药品和曲马多口服复方制剂购销管理的通知》中所列产品名单执行。国家药监局组织制定的《药品网络销售禁止清单(第一版)》，自2022年12月1日起施行。该《清单》包含两大类药品：其一是政策法规明确禁止销售的药品，包括：疫苗、血液制品、麻醉药品、精神药品、医疗用毒性药品、放射性药品、药品类易制毒化学品；医疗机构制剂、中药配方颗粒。其二是其他禁止通过网络零售的药品，包括：一、注射剂(降糖类药物除外)。二、含麻黄碱类复方制剂(不包括含麻黄的中成药)、含麻醉药品口服复方制剂、含曲马多口服复方制剂、右美沙芬口服单方制剂。三、《兴奋剂目录》所列的蛋白同化制剂和肽类激素(胰岛素除外)。四、地高辛、丙吡胺、奎尼丁、哌唑嗪、普鲁卡因胺、普罗帕酮、胺碘酮、奎宁、氨茶碱、胆茶碱、异丙肾上腺素；苯妥英钠、卡马西平、拉莫三嗪、水合氯醛、达比加群酯、华法林、替格瑞洛、西洛他唑、扑米酮、碳酸锂、异氟烷、七氟烷、恩氟烷、地氟烷、秋水仙碱；米非司酮、复方米非司酮、环丙孕酮、卡前列甲酯、雌二醇、米索前列醇、地诺前列酮；法罗培南、夫西地酸、伏立康唑、利奈唑胺、奈诺沙星、泊沙康唑、头孢地尼、伊曲康唑、左奥硝唑、头孢泊肟酯。 (来源：国家药监局医药云端工作室、蒲公英、医药慧）药闻康策新媒体矩阵微信公众号点击下方一键关注【免责声明】1.“药闻康策”部分文章信息来源于网络转载是出于传递更多信息之目的，并不意味着赞同其观点或证实其内容的真实性。如对内容有疑议，请及时与我司联系。2.“药闻康策”致力于提供合理、准确、完整的资讯信息，但不保证信息的合理性、准确性和完整性，且不对因信息的不合理、不准确或遗漏导致的任何损失或损害承担责任。3.“药闻康策”所有信息仅供参考，不做任何商业交易或医疗服务的根据，如自行使用“药闻康策”内容发生偏差，我司不承担任何责任，包括但不限于法律责任，赔偿责任。欢迎转发分享、点赞、点在看

疫苗放射疗法并购

100 项与盐酸普鲁卡因胺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00477	盐酸普鲁卡因胺	C01BA02	DB01035

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
心房颤动	日本	Alfresa Pharma Corp.	1986-02-25
心房扑动	日本	Alfresa Pharma Corp.	1986-02-25
心脏早搏	日本	Alfresa Pharma Corp.	1986-02-25
阵发性心动过速	日本	Alfresa Pharma Corp.	1986-02-25
室性心律失常	美国	Apothecon LLC	1950-06-02

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESC2022	N/A	室性心动过速	68	Oral procainamide	遞壓糧願選積壓顧糧窪(餘積簾蓋製鬱鹽繭廠構): HR = 2.54 (95% CI, 1.06 ~ 6.14), P-Value = 0.03 更多	-	2022-04-04
ESC2022	N/A	室性心动过速	68	Mexiletine		-	2022-04-04
ESC2020	N/A	室性早搏	50	Procainamide	鏇廠糧鹹夢憲齋壓網夢(鹹選糧製製積淵壓鹹餘) = 選網鬱願獵網鹹膚繭醖顧顧衊壓築鹽鹽衊願憲 (鹹鬱膚廠範網廠夢艱願 ) 更多	-	2020-12-11
NCT01205529 (Proc, CTgov)	N/A	心房颤动	161	Procainamide	鑰壓簾衊鏇範構鏇築鹽(餘蓋鬱夢願鏇選構鹹鏇) = 顧廠鬱選獵糧餘齋構壓觸夢廠餘製築夢繭憲夢 (夢淵範顧鏇顧鬱衊鹽積, 製選鏇壓製製醖範獵淵 ~ 憲積鬱願鑰築鹹繭衊顧) 更多	-	2018-05-02